Rubric :   Topical

The role of T790M mutation in first- and second-line therapy of patients with EGFR-positive non-small cell lung cancer
Authors: Storozhenko S.A. Shparyk Ya.V. Т. 13, № 1 (49)
Assessment of overall survival obtained from the real-world study of using the combination of palbociclib with aromatase inhibitors as a first-line treatment of HR+/HER2− metastatic breast cancer
Т. 13, № 1 (49)
Pancreatic Cancer: Innovations For Life
Т. 13, № 1 (49)
ESPEN practical guideline: сlinical nutrition in cancer
Authors: Muscaritoli Maurizio Arends Jann Bachmann Patrick Baracos Vickie ... Т. 13, № 1 (49)
Oncourology. The latest technologies in today’s realities: the results of the PROfound study — the efficacy and safety profile of olaparib in mCRPC
Т. 12, № 3-4 (47-48)
Efficacy of EGFR TKIs of different generations in NSCLC with EGFR mutations: review of clinical studies and our experience
Authors: Kobziev O.I. Boiarskyi O.O. Leonova V.V. Т. 12, № 3-4 (47-48)
Modern treatment approaches of patients with NSCLC and «rare» EGFR mutations and own experience in the treatment of patients with an insertion in the 20th exon
Т. 12, № 3-4 (47-48)
Breast cancer: innovations for life. Part 2
Дата: 2022-09-01
Breast cancer: innovations for life. Part 1
Т. 12, № 1-2 (45-46)
World Conference on Lung Cancer 2020: new in the treatment of advanced/metastatic NSCLC
Т. 11, № 1-2 (41-42)
Comparison of hemostatic agents used in surgery
Authors: Lukashenko A.V. Vinohradova M. T. 10, № 3-4 (39-40)
Five-year overall survival and progression-free survival of patients with advanced NSCLC receiving pembrolizumab
T. 10, № 3-4 (39-40)
The contribution of cytopathologists to the development of morphological diagnostics of oncological diseases in Ukraine (to the 100th anniversary of the National Cancer Institute)»
Authors: Bolgova L.S. Tuganova T.N. Loginova E.A. Alekseenko O.I.... T. 10, № 3-4 (39-40)
Analysis of mortality of patients with colorectal cancer in Kharkiv’s multidisciplinary hospitals
Authors: Yakovtsova I.I. Yakimenko A.S. Ivakhno I.V. Danyliuk S.V.... T. 10, № 3-4 (39-40)
Pembrolizumab is first-line treatment for patients with advanced non-small cell lung cancer in both mono and combination regimens
T. 10, № 1-2 (37-38)

123